Weill Cornell Uptown CRS

Location	Weill Cornell HIV Clinical Trials Unit, 525 East 68th Street, Baker 24 New York, NY 10065 United States of America
CRS Coordinator	Rebecca Fry ref2007@med.cornell.edu 212-746-4166
CRS Leader	Marshall Glesby mag2005@med.cornell.edu 212-746-7134
Studies	A5128: US Genomic Sampling A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study A5354: Early ART in Acute HIV A5359: The LATITUDE Study A5377: Tri-specific Antibody A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) A5360: MINMON Study-Monitoring SOF/VEL in Treatment Naïve, Chronic HCV Participants A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C) A5332: REPRIEVE Trial A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) A5395: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19 A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B